THERAVAC - Evaluation of a therapeutic vaccination strategy for hiv infection (THERAVAC) (LIFE QUALITY) (2002-10-01 - 2006-09-30) (»add to infobox)

Gilbert BEREZIAT, Louise J. GUNNING-SCHEPERS, Michel KLEIN, Walter WAHLI, Frank MIEDEMA, Philippe PRADELLES, Christian BRECHOT, Susan CLARKE, Christian BLOMEYER

UNIVERSITE PIERRE ET MARIE CURIE (FR101 - Paris) (France), ACADEMIC MEDICAL CENTRE BY THE UNIVERSITY OF AMSTERDAM (NL326 - Groot-Amsterdam) (Netherlands), AVENTIS PASTEUR SA (FR716 - Rhône) (France), CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CH011 - Vaud) (Switzerland), CLB - SANQUIN BLOOD SUPPLY FOUNDATION (NL326 - Groot-Amsterdam) (Netherlands), COMMISSARIAT A L'ENERGIE ATOMIQUE (CEA) (FR105 - Hauts-de-Seine) (France), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France), LIBRAPHARM LTD (UK521 - Berkshire) (Great Britain), UNIVERSITAET REGENSBURG (DE238 - Regensburg, Landkreis) (Germany)

Highly active antiretroviral therapy (HAART) dramatically decreases in HIV-related morbidity but does not eradicate HIV and is associated with severe toxicities. To improve clinical management of HIV infection the Theresa Demonstration Project will evaluate a new strategy of immunotherapy using highly attenuated poxvirus-based anti-HIV vaccines (NYVAC/MVA) in phase I/II clinical trials in HIV-infected patients. The objectives of the Project are to demonstrate1) the safety of these vaccines in HIV-infected patients under HMRT, 2) their capacity to increase numbers and breadth of HIV-specific T cells in order to restore a strong immune control of HIV, compared to the Canary pox vaccine, 3) to allow prolonged interruptions of treatments. A principal deliverable of Theresa is to show that the collaboration of new vaccines produced in Europe and antiretroviral can limit time on therapy and associated drug toxicity and costs.

PERSONS (9/9)

RELATED NAVIGATION AREA(S) (2/2)